Assessment of the dynamics of cardiological markers (LV systolic function, NT-proBNP) and its relationship with actual adherence to drug therapy in patients with stable coronary artery disease after planned myocardial revascularization

Objective: to evaluate the dynamics of left ventricular ejection fraction (LVEF) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with stable coronary artery disease (CAD) before and after planned myocardial revascularization and to analyze their association with actual adherence to drug therapy. Material and methods: a cross-sectional observational study was conducted based on data from a specialized registry. The study included 300 patients with stable CAD, functional class III (CCS), aged 50–80 years, hospitalized for elective myocardial revascularization: 107 (35.7%) for coronary artery bypass grafting (CABG) and 193 (64.3%) for percutaneous coronary intervention (PCI). Adherence was assessed using the National Society for Evidence-Based Pharmacotherapy (NSEBP) scale (potential, overall actual, and actual adherence to specific drugs and drug classes). The dynamics of markers were evaluated 6 days after surgery, taking into account thresholds for significant changes: ΔLVEF >5–10%, ΔNT-proBNP >20%. The lowest actual adherence was recorded for statins (62% of patients took >80% of prescribed doses), and the highest for antiplatelet agents (86%). Results: total actual adherence moderately correlated with a decrease in NT-proBNP (ρ = 0.38; p = 0.001) but weakly with LVEF dynamics (ρ = 0.29; p = 0.018). Potential adherence showed no significant correlation (ρ = 0.09; p = 0.32). The greatest relative reduction in NT-proBNP was observed in the group with the highest baseline level (Group C – 405 pg/mL, reduction 37%), which is explained by regression to the mean. In the group with high actual adherence (Group A), the reduction in NT-proBNP was 26%. Low adherence to statins was associated with a smaller reduction in NT-proBNP (16% vs. 28%, p = 0.003). LVEF dynamics at 6 days did not differ between adherence groups (p = 0.21). Conclusion: actual adherence is associated with NT-proBNP dynamics but not with early LVEF dynamics. The lowest adherence was observed for statins, which requires additional attention. Accounting for analytical variability (thresholds for significant changes) is necessary for correct interpretation of the results.

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200. Erratum in: Eur Heart J. 2018;39(10):860. DOI: 10.1093/eurheartj/ehw128

2. Braunwald E. Heart failure. JACC Heart Fail. 2013;1(1):1-20. DOI: 10.1016/j.jchf.2012.10.002 3. Ordonez-Llanos J, Collinson PO, Christenson RH. Amino-terminal pro-B-type natriuretic peptide: analytic considerations. Am J Cardiol. 2008;101(3A):9-15. DOI: 10.1016/j.amjcard.2007.11.013

3. Meijers WC, van der Velde AR, Muller Kobold AC, Dijck-Brouwer J, Wu AH, Jaffe A, et al. Variability of biomarkers in patients with chronic heart failure and healthy controls. Eur J Heart Fail. 2017;19(3):357-365. DOI: 10.1002/ejhf.669

4. Wu AH. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J. 2006;152(5):828-834. DOI: 10.1016/j.ahj.2006.08.021

5. Reibis R, Salzwedel A, Bonaventura K, Völler H, Wegscheider K. Improvement of left ventricular ejection fraction in revascularized postmyocardial patients: indication for statistical fallacy. BMC Res Notes. 2017;10(1):244. DOI: 10.1186/s13104-017-2562-4

6. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol. 2005;34(1):215- 220. Erratum in: Int J Epidemiol. 2015;44(5):1748. DOI: 10.1093/ije/dyh299

7. Dauerman HL, Reardon MJ, Popma JJ, Little SH, Cavalcante JL, Adams DH, et al. Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement. Circ Cardiovasc Interv. 2016;9(6):e003425. DOI: 10.1161/CIRCINTERVENTIONS.115.003425

8. Лукина Ю.В., Кутишенко Н.П., Марцевич С.Ю., Шепель Р.Н., Драпкина О.М. Методические рекомендации: «Приверженность к лекарственной терапии у больных хроническими неинфекционными заболеваниями. Решение проблемы в ряде клинических ситуаций». Профилактическая медицина. 2020;23(3‑2):42‑60. DOI: 10.17116/profmed20202303242

9. Лукина Ю.В., Марцевич С.Ю., Кутишенко Н.П. Шкала Мориски-Грина: плюсы и минусы универсального теста, работа над ошибками. Рациональная фармакотерапия в кардиологии. 2016;12(1):63-65 DOI: 10.20996/1819-6446-2016-12-1-63-65

10. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27(3):330-337. DOI: 10.1093/eurheartj/ehi631